1USC Department of Family and Preventive Medicine, Professor of Obstetrics and Gynecology University of South Carolina School of Medicine, Columbia, SC; 2Division of Gynecologic Oncology, Department of Obstetrics & Gynecology and Women's Health, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY; 3Department of Obstetrics and Gynecology, Virginia Commonwealth University School of Medicine, Richmond, VA; 4Women's Health Nurse Practitioner, Gyn Cancer and Pelvic Surgery, West Orange, NJ; 5Pima County Health Department, Tucson, AZ; 6Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD; 7Palmetto Health/University of South Carolina School of Medicine Preventive Medicine Residency Program, Columbia, SC; and 8Department of Obstetrics, Gynecology, & Women's Health, Rutgers New Jersey Medical School, Newark, NJ
Reprint requests to: Edward J. Mayeaux, Jr, MD, DABFM, FAAFP, DABPM, USC Department of Family and Preventive Medicine, University of South Carolina School of Medicine, 3209 Colonial Dr, Columbia, SC 29203. E-mail: [email protected]
There was no source of financial support for the project other than logistic support from the American Society for Colposcopy and Cervical Pathology. For personnel, “This project was partially supported by the Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services (HHS) under Grant Number D33HP26995 (Preventive Medicine Residencies - US $1,498,629). This information or content and conclusions are those of the authors and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS, or the US Government.”
M.H.E. has advised but does not receive an honorarium from any companies. In specific cases, his employer has received payment for his consultation from Photocure, Papivax, Inovio, PDS Biotechnologies, Natera, and Immunovaccine. If travel is required for meetings with any industry, the company pays for M.H.E.'s travel-related expenses. In addition, his employers have received grant funding for research-related costs of clinical trials that M.H.E. has been the overall project investigator or local project investigator for the past 12 months from Astra Zeneca, Baxalta, Pfizer, Inovio, Fujiboro, and Eli Lilly. K.C. reports that she is on a speaker's bureau and advisory board for Hologic, Inc, and an advisory board for Symbiomix Therapeutics. The rest of the authors have declared they have no conflicts of interest.
No institutional review board approval or written consent was required because the research was literature based and did not involve human subjects.
